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Introduction: Despite cooling, adverse outcomes are
seen in up to half of the surviving infants after
neonatal encephalopathy. A number of novel adjunct
drug therapies with cooling have been shown to be
highly neuroprotective in animal studies, and are
currently awaiting clinical translation. Rigorous
evaluation of these therapies in phase II trials using
surrogate MR biomarkers may speed up their bench to
bedside translation. A recent systematic review of
single-centre studies has suggested that MR
spectroscopy biomarkers offer the best promise;
however, the prognostic accuracy of these biomarkers
in cooled encephalopathic babies in a multicentre
setting using different MR scan makers is not known.
Methods and analysis: The MR scanners (3 T;
Philips, Siemens, GE) in all the participating sites will
be harmonised using phantom experiments and
healthy adult volunteers before the start of the study.
We will then recruit 180 encephalopathic infants treated
with whole body cooling from the participating centres.
MRI and spectroscopy will be performed within
2 weeks of birth. Neurodevelopmental outcomes will be
assessed at 18–24 months of age. Agreement between
MR cerebral biomarkers and neurodevelopmental
outcome will be reported. The sample size is calculated
using the ‘rule of 10’, generally used to calculate the
sample size requirements for developing prognostic
models. Considering 9 parameters, we require 9×10
adverse events, which suggest that a total sample size
of 180 is required.
Ethics and dissemination: Human Research Ethics
Committee approvals have been received from Brent
Research Ethics Committee (London), and from
Imperial College London (Sponsor). We will submit the
results of the study to relevant journals and offer
national and international presentations.
Trial registration number: Clinical Trials.gov
Number: NCT01309711.
BACKGROUND
Neonatal encephalopathy occurs in approxi-
mately 1–2 per 1000 live births in high-income
countries.1–4 The incidence in low-income and
middle-income countries is much higher.5
Often, neonatal encephalopathy occurs unex-
pectedly following an otherwise uneventful
pregnancy. Before the widespread implemen-
tation of the therapeutic hypothermia, 20–
25% of the affected infants died in the ﬁrst few
days after birth, and up to 75% of the survivors
developed signiﬁcant lifelong disabilities3 6
resulting in a substantial burden for the indi-
vidual, their family and society.7
In the past 5 years, three major clinical
trials of whole body or selective head cooling
therapy8–10 showed signiﬁcant reduction in
death (risk ratio (RR)=0.8; 95% CI 0.7 to 0.9;
p=0.005) and improvement in survival with
normal neurological outcome (RR=1.5; 95%
CI 1.2 to 1.9; p<0.001), after neonatal
encephalopathy.11 The protective effect of
therapeutic hypothermia persists into early
childhood.12 Unfortunately, up to 50% of sur-
viving infants still have adverse outcomes.13
For these reasons, there has been a
renewed interest in other potential neuro-
protectants, or adjunctive therapies, most of
which have shown promising results in a pre-
clinical stage or in pilot studies.14 15
Unfortunately, evaluating clinical efﬁcacy
of these therapies is extremely challenging
for a number of reasons. First, the sample
Strengths and limitations of this study
▪ First and largest multicentre prospective study
examining the prognostic accuracy of cerebral
MR biomarkers in neonatal encephalopathy.
▪ Robust optimisation, harmonisation and quality
assurance of MR biomarkers.
▪ All the three major makers of MR scanners
(Phillips, Siemens and GE) included.
▪ Only centres with access to 3 T MR scanners are
included.
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sizes for an adequately powered clinical trial of an
adjunct therapy will be exceedingly high. Second, the
effects on long-term outcome are likely to be more
subtle and may require several years of follow-up for
adequate evaluation. Finally, the intervention and the
outcome measures of these neuroprotectants are likely
to be highly heterogeneous (eg, different protocols,
dosage and timing of the intervention) unlike the three
major cooling trials, thus reducing the chances of robust
meta-analysis.
MR biomarkers of injury severity have the potential to
overcome many of these challenging impediments to
progress. In the past decade, such MR biomarkers have
enhanced our ability to identify, assess the onset and
quantify the features of brain injury soon after birth.16
These modalities may be valuable as surrogate outcome
measures of the treatment effects of adjunct neuropro-
tective therapies.
While conventional and diffusion-weighted neonatal
MRI is currently the main modality used for the assess-
ment of injury and prediction of outcome after neonatal
encephalopathy, it is considered subjective and requires
considerable time and experience for interpretation.
Measurements of basal ganglia or thalamic metabolites by
proton MR spectroscopy (MRS), in particular the ratio of
lactate/N-acetylaspartate (Lac/NAA), have been shown in
meta-analyses to be the most accurate cerebral MR biomar-
kers for predicting medium-term adverse neurological
outcome currently available.16 Unfortunately, these data
come from a very few, small single-centre studies, using a
variety of MR sequences on 1.5 T MR scanners,17–19 and
their applicability over a wider range of centres is not
known. There is very little information available on the use
of these MRS biomarkers on babies who have received
rescue hypothermic neuroprotective therapy and in
general have lesser degrees of injury than in earlier
cohorts; additionally, there is a lack of data at 3 T, which is
expected to be the standard platform for neonatal neuroi-
maging in the next decade.
Metabolite peak area ratios are affected by patho-
physiological changes in both NAA and Lac, which follow
very different time courses and which can be variably and
independently affected by neuroprotective therapies and
intercentre scanner differences.20 Hence, despite the
good reported prediction of outcome with metabolite
ratios, absolute quantiﬁcation of [NAA], even though
technically more challenging to estimate than metabolite
peak area ratios, may offer several advantages. NAA is the
second most abundant amino acid in the nervous system,
and is almost exclusively neuronal. Therefore, it has been
used as a surrogate index of neuronal survival. NAA con-
centrations measured by 1H MRS are theoretically abso-
lute, reproducible,21 should not vary with scanner
magnetic ﬁeld strength, investigatory centre20 and correl-
ate well with NAA concentrations measured by high per-
formance liquid chromatography.22 23 Therefore, it is
considered an ideal biomarker.
Smaller single-centre studies have also shown good
correlation of reduced whole brain fractional anisotropy
(FA; analysed by Tract Based Spatial Statistics—TBSS)
with adverse outcomes at 2 years.24 25 TBSS is an auto-
mated observer-independent method of aligning FA
images from multiple subjects to make non-biased assess-
ments of localised changes in the major white matter
tracts,25 and therefore is a useful tool for evaluating
treatment efﬁciencies of neuroprotective therapies on
diffusion tensor-based biomarkers.
The current study aims to harmonise the acquisition,
and to qualify the use of novel quantitative cerebral
MRI and MRS biomarkers for accurate prognostication
of medium-term adverse outcomes in term and near
term infants after neonatal encephalopathy, across
several tertiary neonatal centres in the UK, and
worldwide.
METHODS AND DESIGN
This is a prospective multicountry observational study,
which will be conducted in three phases.
Phase A: MRS phantoms will be prepared (expected
life span 2 years) and scanned in 3 T MR scanners at the
participating centres. The intercentre variability of
metabolite ratios and concentrations will be examined
and any effects will be investigated.
Phase B: Five healthy adult volunteers will be scanned
at each site. Adult volunteers should be of sound health,
between 20 and 45 years of age, and not pregnant at the
time of scans. The intercentre variability of metabolite
measurements will be examined and any effects will be
investigated further.
Phase C: Infants with neonatal encephalopathy of pre-
sumed hypoxic-ischaemic origin and born at term and
who have had rescue hypothermic neuroprotection will
be recruited. The index tests (cerebral MR biomarkers)
and neurological outcome at 18–24 months of age will
be performed independently, and masked to each
other.
Inclusion criteria
Term and near term infants (36–43 weeks gestation)
with evidence of neonatal encephalopathy and treated
with therapeutic hypothermia at the participating neo-
natal units will be eligible for recruitment.
Exclusion criteria
▸ Life-threatening congenital malformations
▸ Syndromic infants, and babies with neurometabolic
diseases
▸ Neurodevelopmental follow-up not possible
▸ Death/withdrawal of life support before completion
of 72 h of therapeutic hypothermia
▸ Lack of parental consent or inability to scan within
2 weeks of birth
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Clinical assessment
All infants will have standard intensive care management
for neonatal encephalopathy. Gestational age; birth
weight and head circumference; the Apgar score at 1, 5
and 10 min; umbilical cord pH; base deﬁcit and Lac or
blood gas pH; base deﬁcit; Lac within 1 h of birth will
be recorded. The babies will have a cranial ultrasound
scan on admission, at 24 h and 3–4 days for detection of
malformations, bleeds, loss of normal tissue differenti-
ation and evolving tissue injury.26 Amplitude-integrated
EEG (aEEG) will be performed over the ﬁrst 48 h, as
part of standard clinical care. The aEEG background
activity will be classiﬁed according to voltage criteria and
by background pattern.27 We will perform a scored
neurological assessment (National Institute of Child
Health and Human Development scoring system28 29),
on admission, daily during the ﬁrst 3 days and an add-
itional more detailed assessment before discharge.
Additional items will include: head circumference, head
control, axial tone, limb tone, seizures, visual ﬁxation
and following, squint, hearing, feeding.
MRI protocol
Acquisition
MRI will be performed between 4 and 14 days after birth
(ie, after completion of therapeutic hypothermia) in all
infants, following informed parental consent. Existing
MR scanning protocols will be followed in the individual
centres with regard to sedation and monitoring.
MRI
Detailed MR sequences for different scanners will be
developed into individual MR taskcards at each site.
Typical MR parameters on a Philips 3 T scanner are:
T1-weighted three-dimensional (3D) magnetisation-
prepared rapid gradient-echo (sagittal, repetition time
(TR)=17 ms, echo time (TE)=4.6 ms, ﬂip angle=13°,
inversion time=1465 ms, 0.8×0.8×0.5 mm3 voxels),
T2-weighted 2D turbo spin echo (axial, TE=130 ms,
TR=8800 ms, 0.5×0.5×3 mm3 voxels) and diffusion
tensor imaging (DTI; 32 direction 2D spin-echo echo-
planar imaging, b=750 s/mm2, TR=7860 ms, TE=49 ms,
1.75×1.75×2 mm3 voxels, SENSE factor ×2).
Conventional MRI score
Each image will be reported systematically by an experi-
enced neonatal neurologist blinded to the clinical
history but not gestational age and age at scan. Each
scan will be assessed for anatomy, established injury,
atrophy, haemorrhage and ventriculomegaly. Based on
the scoring system developed by Rutherford et al,30 brain
tissue injury will be scored from 0 to 3 for basal ganglia/
thalami, white matter and cortex (0=normal, 1=mild
signal abnormality, 2=moderate signal abnormality,
3=severe signal abnormality) and the posterior limb of
the internal capsule scored from 0 to 2, as normal,
equivocal or abnormal. The presence of focal hemi-
spheric lesions and their site will also be noted.
MRS metabolite peak area ratios
Single-voxel point-resolved spectroscopy (PRESS),
15×15×15 mm3 cubic voxel in the left thalamus,
TR=2288 ms/TE=288 ms (16 averages with 8 phase
cycles, water suppressed) and TR=2060 ms/TE=60 ms (8
averages with 8 phase cycles, water suppressed).
Metabolite peak area ratios involving NAA, total choline,
total creatine and Lac will be derived.
MRS quantification of [NAA]
Same thalamic voxel; additional PRESS scans: (1)
TE=60 ms, TR=5000 ms, (8 averages with 8 phase cycles,
water suppressed) (2) TE=60, 124, 205, 316, 495, and
1000 ms, each with TR=10s+TE, with one average of
eight phase cycles, and without water suppression. NAA
concentration will be derived from an assumed brain
water concentration by comparing the T2-corrected fully
relaxed NAA and brain water signals.
TBSS analysis
Whole-brain white matter FA with TBSS will be analysed
using the Functional MRI of the Brain Software Library
(FSL, V.4.1)31 and the Diffusion Tensor Imaging ToolKit
(DTI-TK, V.2.3.1).32 Diffusion-weighted data will be cor-
rected for motion and eddy current distortion, segmen-
ted to exclude extracerebral tissue, and used to
reconstruct the diffusion tensor volume, with FSL. The
diffusion tensor volumes from all the participants will be
spatially normalised with an optimised pipeline in
DTI-TK, prior to TBSS analysis.33 An FA threshold
(>0.10) will be required to identify the major white
matter tracts but to exclude peripheral tracts. TBSS will
be used to assess the relationship between FA and
outcome. The presence of group-wise FA differences
with p<0.05, corrected for multiple comparisons using
threshold-free cluster enhancement,34 will be considered
statistically signiﬁcant.
MR Spectroscopy Analysis
The raw data will be taken from MR scanners, postpro-
cessed using software developed in-house, and LCModel
(LCModel Inc, Oakville, Ontario, Canada, V.6.1) will be
used to calculate metabolite peak area ratios and
concentrations.
Neurodevelopmental outcome
A standardised, validated and scorable neurological
examination will be performed;35 the presence and type
of cerebral palsy determined according to Gorter et al36
and severity classiﬁed using the Gross Motor Function
Classiﬁcation System (GMFCS). Neurodevelopmental
outcome will be assessed using the Bayley Scales of Infant
Development (BSID-III), by trained and certiﬁed exami-
ners. Vision and audiometric evaluations37 will be col-
lected alongside anthropometric data (weight, height
and head circumference) as part of the follow-up evalua-
tions. Infants will be tracked and undergo follow-up at
network centres with evaluations at 18–24 months.
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Outcome will be assessed according to the neuro-
logical examination score; the GMFCS level; and the
cognitive, language and motor composite scores. These
variables provide quantitative data that can be compared
with MR measures.
Severe disability will be deﬁned as any one of the fol-
lowing: Bayley III, both cognitive and language compos-
ite scores <70, GMFCS level 3–5, hearing impairment
requiring hearing aids or blindness. Moderate disability
will be deﬁned as both cognitive and language compos-
ite scores between 70 and 84 and one or more of the fol-
lowing: GMFCS level 2, hearing impairment with no
ampliﬁcation or a persistent seizure disorder.
The outcomes will also be assessed by categorisation
of these scores and by including mortality as an
outcome. Adverse outcome will be deﬁned as death or,
in survivors, moderate or severe disability.
Outcomes
The primary outcome is to examine the accuracy of
quantitative cerebral MR biomarkers for predicting
adverse 18–24-month neurodevelopmental outcome in
infants who had neonatal encephalopathy treated with
therapeutic hypothermia, in a multicentre setting.
The secondary outcomes are the intercentre variability
of proton MRS measurements and the incremental ben-
eﬁts of quantitative MR biomarkers for predicting
adverse outcomes when compared with conventional
MR assessment and bedside assessments and investiga-
tions such as the Apgar score at 1, 5 and 10 min; umbil-
ical cord pH; base deﬁcit and Lac or blood gas pH; base
deﬁcit; Lac within 1 h of birth; abnormal aEEG (voltage
criteria: upper margin <10 µV, lower margin <5 µV) at
48 h; neurological examination at discharge.
Sample size calculation and data analysis
The primary outcome will be unfavourable outcome at
18–24 months (yes/no). Approximately 50% of the
infants are expected to have an unfavourable outcome.
Since this is binary, multivariable logistic regression will
be used to develop risk prediction models. The predic-
tors in these models will be: [NAA], Lac/NAA peak
area ratio, white matter FA (all continuous); aEEG at
48h (categorical with three levels) and clinical examin-
ation at discharge (binary). Models will be validated
using 10-fold cross-validation, and will be assessed with
respect to calibration and discrimination. Calibration
and discrimination will be measured using calibration
slopes and receiver operating characteristic curves,
respectively. Shrinkage techniques will be used to
adjust for overﬁtting, thus improving calibration.
Sensitivity and speciﬁcity will be calculated at selected
cut-off points.
The sample size is calculated using the ‘rule of 10’,2
generally used to calculate the sample size requirements
for developing prognostic models. The multivariable risk
model will contain seven predictors that are modelled
using nine parameters to examine the incremental
beneﬁts of various clinical, bedside (aEEG) and MR bio-
markers (conventional MR reporting, MRS peak area
metabolite ratios and [NAA]). Considering nine para-
meters, we require 9×10 adverse events, which suggest
that a total sample size of 180 is required.
Study approval
North London Research Ethics Committee has approved
the MARBLE study (13HH1843). Imperial College
London is the sponsor for the study. All participating
centres have site-speciﬁc approval, and research con-
tracts with Imperial College London will be setup before
the start of the study.
Consent
Informed written parental consent will be obtained as
stipulated by the research ethics committee, prior to
recruitment.
DISCUSSION
The use of a biomarker to measure the treatment effects
of an intervention is complex. Wrong surrogate bio-
marker approaches can result not only in wasted effort
and in resources, but can also cause patient harm.
However, there are many instances where judicious use
of imaging biomarkers has resulted in rapid bench to
bedside translation and remarkable scientiﬁc progress,
for example, in oncology.38
Furthermore, the use of cerebral MR biomarkers in
multicentre studies can be particularly challenging.
Hence, careful and robust optimisation of sequences
and harmonisation of MR scanners and techniques is
mandatory.
This study can help identify new biomarkers for accur-
ate prognostication of long-term adverse outcomes in
term and near term infants after neonatal
encephalopathy.
Moreover, such surrogate cerebral MR biomarkers
could give a beneﬁcial contribution to future clinical
trials. In fact, these biomarkers have far less variability
than clinical neurodevelopmental outcome measure-
ments, and hence the required sample sizes for equiva-
lent risk reductions may be reduced. A further strength
is that these outcomes can be measured soon after the
perinatal intervention (ie, during the neonatal period
itself) rather than after several years. For these reasons,
they would enable direct comparison of multiple inter-
ventions using factorial trial designs with minimal
resources and negate the inﬂuence of confounding
factors. Thus, an approach using surrogate MR biomar-
kers has the potential to screen out the most promising
therapies and to make ‘go’ or ‘no go’ decisions before
phase III clinical trials.
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